Barrick Announces Evaluation of an Initial Public Offering of its North American Gold Assets

(TSX:ABX),(NYSE:B),(LSE:0R22), Contemplated IPO to highlight the value of North American gold assets by creating a focused publicly traded equity (“NewCo”) Barrick would maintain a significant controlling interest in NewCo Company will update market on progress at Full Year 2025 Results in February 2026 TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) — Barrick Mining Corporation (NYSE:B)(TSX:ABX) (“Barrick” […]

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

(NASDAQ:AUTL), LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced the appointment of Ryan Richardson to the Company's Board of Directors. Mr. Richardson brings more than 20 years of strategy and corporate

Highlander Silver Reports Record Results and New Discovery: 23.9m at 20.82 g/t Gold and 31.53 g/t Silver and 23.4m at 11.70 g/t Gold and 26.10 g/t Silver in Shallow Drilling

(TSX:HSLV), TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) — Highlander Silver Corp. (TSX: HSLV; “Highlander Silver” or the “Company“) is pleased to report exceptional assay results from shallow drilling at its expanding Bonita vein system. These results include the highest grades reported to date and the discovery of a new zone in step-out drilling over 200m

Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly

(NASDAQ:ADVM), REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy as a potential One And DoneTM treatment to preserve sight for life, today announced that it has mailed a letter to its stockholders in connection with its pending transaction to

Mobix Labs Expected to Report 54% YoY Revenue Growth Alongside Improved Operating Performance

(NASDAQ:MOBX), ~ Gross margin expected to increase from 39.6% to 50.5% ~ ~ Loss from operations expected to be cut nearly in half ~ IRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — Mobix Labs, Inc. (“Mobix” or the “Company”) today announced selected preliminary, unaudited financial results for its fourth quarter and fiscal year ended September

Mirasol Launches Exploration Season at Sobek Copper-Gold Project in the Vicuna District, Chile

(TSX-V:MRZ),(Pinksheets:MRZLF),(PinkSheets:MRZLF), Located just 7 km west of Filo del Sol in the Vicuna District, the 46 South target is at the south end of a 3 km N-S trending corridor of mineralization at Sobek Central The 46 South epithermal and underlying porphyry target sits on the margin of a district scale magnetic high where coincident

Carlton Precious Provides Esquilache Project Update

(TSX-V:CPI),(OTC US:NBRFF),(OTCQB:NBRFF),(OTC US:CPIFF),(OtherOTC:CPIFF), TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) — Carlton Precious Inc. (TSX-V: CPI | OTCQB: CPIFF) (“Carlton” or the “Company“) is pleased to provide an update to investors on its Esquilache Silver project (“Esquilache” or the “Project”) located in the Puno region of Southern Peru. Esquilache covers 1,600 hectares that include historical mine

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

(NASDAQ:ELDN), IRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will participate in a fireside chat at the upcoming 37th Annual Piper Sandler Healthcare Conference on Thursday, December 4, 2025 at 8:50 a.m. ET (5:50 a.m. PT). To register in

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

(NASDAQ:MGX), EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that the Company will present new preclinical data supporting the third target, APOC3, in its collaboration with Ionis Pharmaceuticals at

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

(NASDAQ:PMN), Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will be participating in a fireside chat and investor one-on-one meetings at the 8th Annual

Scroll to Top